Matthew A. Pearson
Partner
Areas of Focus
- Patent Litigation
- Life Sciences Intellectual Property
- Intellectual Property
- Strategic IP Counseling
- Health Care & Life Sciences
- Technology
- Inter Partes Review
- Supreme Court & Appellate: IP
- Litigates patent cases in the life sciences.
- Has extensive trial experience in biologics and immunology patent cases.
- Holds a Ph.D. in biochemistry and worked at the National Institutes of Health.
Dr. Matthew Pearson litigates patent cases about pharmaceuticals, chemistry and biology, with a particular focus on biologics and antibody technology.
In his work as a scientist, he focused on the mechanism and three-dimensional molecular structures of proteins using x-ray crystallography. This scientific background has allowed Matthew to successfully litigate major patent disputes involving biologics, an extremely competitive and technically complex field. His experience as a scientist is critical to designing effective case strategy and in establishing credibility with the scientists who work for his clients.
- Represented Bristol-Myers Squibb, Ono Pharmaceutical Co. and Japanese immunologist Dr. Tasuko Honjo in patent litigation involving revolutionary immuno-oncology treatment methods. The team’s work contributed to a worldwide settlement that included an initial payment by defendant Merck & Co., Inc. of $625 million and payment of ongoing royalties through 2026.
- Represented plaintiff 3M Company in a patent infringement dispute against competitor Kerr Corporation involving 3M’s innovative dental composite materials. After successive victories for 3M in connection with Markman proceedings and Daubert motions, the case settled in December 2019.
- Represented pharmaceutical companies in the correction of inventorship action related to patents involving methods of treatment for cancer with biologics.
- Represented pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigation related to treatments for schizophrenia.
- Served as part of the trial team that won a jury verdict for client Janssen Biotech Inc. in a patent infringement case brought by Abbott GmbH & Co. The jury returned a verdict that claims in two patents asserted against Janssen’s antibody drug product Stelara® were invalid. Responsible for direct and cross-examination of technical experts.
EducationJ.D., University of Pennsylvania Law School, summa cum laude, 2005
Ph.D., Cornell University, 1999
B.S., Michigan State University, with high honors, 1993
J.D., University of Pennsylvania Law School, summa cum laude, 2005
Ph.D., Cornell University, 1999
B.S., Michigan State University, with high honors, 1993
ClerkshipsU.S.D.C., District of Delaware
U.S.C.A., 3rd Circuit
U.S.D.C., District of Delaware
U.S.C.A., 3rd Circuit
Bar AdmissionsDelaware
Pennsylvania
U.S. Patent and Trademark Office
Delaware
Pennsylvania
U.S. Patent and Trademark Office
- The Legal 500 US, Patents: Litigation (Full Coverage), 2021 and 2023.
- Philadelphia Business Journal, Best of the Bar: Philadelphias Top Lawyers, 2020.
- IAM Patent 1000—The World’s Leading Patent Professionals, leading private patent litigator in Philadelphia, 2019 - 2021.
- Pennsylvania Super Lawyers, Intellectual Property Litigation, 2013-2018.
- Adjunct professor, University of Pennsylvania Law School, patent litigation.
- Frequent speaker on patent litigation, biologics and biosimilars.
